Connect Biopharma Holdings Limited CNTB
0.69 USD +0.01 (+0.98%)
At closeNov 11, 2026, 7:41 PM EST
0.70 +0.01 +0.93%
After hours · Nov 11, 7:41 PM ET
0.6801 Day range 0.7212
0.682 52-week range 3.69
- YTD
- -75.57%
- 1 year
- -54.68%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
seekingalpha.com Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
zacks.com Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
zacks.com Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate…- benzinga.com Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4 Leerink Partners analyst Will Soghikian assumes Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $4.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
defenseworld.net Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
marketbeat.com Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
benzinga.com Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
benzinga.com Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.
benzinga.com Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.
seekingalpha.com Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
benzinga.com BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5 BTIG analyst Julian Harrison maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $10 to $5.
benzinga.com Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The…
- benzinga.com Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85% Key topline results include:Rademikibart significantly reduced the rate of treatment failure by 81% through Week 4 compared to placebo (p=0.0122)Rademikibart significantly reduced the rate of new…
globenewswire.com Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation – Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
benzinga.com Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5 Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.
benzinga.com HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.- benzinga.com Canaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6 Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $7 to $6.
seekingalpha.com Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
benzinga.com BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $10 price target.
benzinga.com Why Is Connect Biopharma Stock Trading Lower on Tuesday? Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart.
benzinga.com Why Is Connect Biopharma Stock Trading Lower on Tuesday? Connect Biopharma asthma drug rademikibart misses primary endpoint but shows improved lung function and a favorable safety profile.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1…
benzinga.com Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate at 28 Days by 66% and Improved Lung Function Vs. Placebo Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory…
globenewswire.com Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation – Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
globenewswire.com Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's after-market session. The company's market cap stands at $5.1 million. Picard Medical (AMEX:PMI) stock…
globenewswire.com Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update – Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – –…
defenseworld.net Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29 Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm,…
seekingalpha.com Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and…
benzinga.com Oppenheimer Initiates Coverage On Connect Biopharma Hldgs with Outperform Rating, Announces Price Target of $8 Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $8.- benzinga.com Piper Sandler Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $7 Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight rating and announces Price Target of $7.
benzinga.com HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.- benzinga.com Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 Inflammation – On track to also complete enrollment in the Seabreeze STAT COPD study this month –– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –– Strong balance sheet…
globenewswire.com Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma – On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.- benzinga.com Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6 Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $6.
marketbeat.com Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026 Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits…- benzinga.com Cantor Fitzgerald Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $4 Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight rating and announces Price Target of $4.
globenewswire.com Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on…- benzinga.com Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 78.95 percent decrease over…